Pathways towards human immunodeficiency virus elimination
Prasanta K. Dash, Bhavesh D. Kevadiya, Hang Su and 2 more
EBioMedicine · 2020
doi:10.1016/j.ebiom.2020.102667 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Antiretroviral therapy (ART) suppresses human immunodeficiency virus (HIV) infection. Research seeking to transform viral suppression into elimination has generated novel immune, chemical and molecular antiviral agents. However, none, to date, have excised latent integrated proviral DNA or removed infected cells from infected persons. These efforts included, but are not limited to, broadly neutralizing antibodies, “shock” and “kill” latency-reversing agents, innate immune regulators, and sequential long-acting antiretroviral nanoformulated prodrugs and CRISPR-Cas9 gene editing. While, the latter, enabled the complete excision of latent HIV-1 from the host genome success was so far limited. We contend that improvements in antiretroviral delivery, potency, agent specificity, or combinatorial therapies can provide a pathway towards complete HIV elimination. Keywords: Antiretroviral therapy, Latency reversing agents, Broadly neutralizing antibodies, Long-acting slow-effective release antiretroviral therapy, HIV-1 tissue reservoirs, CRISPR-Cas9 gene editing
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.